Sutro Biopharma STRO Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$153.6M+19.6% | -$191.09M+11.8% | -$216.77M-3.9% | -$208.7M+14.9% | -$245.22M-7.8% | ||
| $6.7M-8.5% | $7.32M-3.2% | $7.57M+1.4% | $7.47M+1.5% | $7.36M+1.9% | ||
| $10.03M-28.4% | $14.01M-23.3% | $18.27M-21.5% | $23.26M-3.7% | $24.16M-2.1% | ||
| —— | $1.69M+33.3% | $1.27M+50.0% | $847K+100% | $423.5K— | ||
| -$1.13M+75.9% | -$4.69M0.0% | -$4.69M-415% | -$912K+95.4% | -$19.7M+33.0% | ||
| —— | —— | —— | -$1.73M-339% | $722K+2.3% | ||
| -$6.2M-457% | $1.74M+2,346% | $71K— | —— | —— | ||
| -$18.34M+5.2% | -$19.35M-160% | -$7.45M-344% | $3.05M-67.7% | $9.46M-20.2% | ||
| -$512K+10.3% | -$571K+7.3% | -$616K+3.6% | -$639K+14.2% | -$745K+2.7% | ||
| -$66.91M+4.0% | -$69.73M— | —— | —— | —— | ||
| -$7.77M-3.8% | -$7.48M-3.8% | -$7.2M-3.9% | -$6.93M-3.9% | -$6.67M-4.0% | ||
| -$151.61M+14.5% | -$177.23M+20.4% | -$222.53M+10.6% | -$248.86M-21.9% | -$204.14M-1.6% | ||
| —— | —— | —— | —— | —— | ||
| $16.01M-64.4% | $45.01M-60.4% | $113.8M-48.5% | $221.1M+60.0% | $138.15M-36.8% | ||
| —— | —— | —— | —— | —— | ||
| —— | $0— | —— | —— | —— | ||
| $28K— | $0— | —— | —— | —— | ||
| $312K-6.0% | $332K+14.9% | $289K-14.5% | $338K+7.3% | $315K-38.1% | ||
| —— | —— | —— | —— | $97.57M+3.7% | ||
| -$34.45M+74.3% | -$134.08M-21.3% | -$110.55M-313% | -$26.76M-165% | $41.01M-66.1% | ||
| $53K-29.3% | $75K-96.8% | $2.37M-0.1% | $2.37M-86.5% | $17.52M0.0% | ||
| $2.76M-19.5% | $3.44M-22.7% | $4.44M-30.4% | $6.39M-21.9% | $8.18M-15.8% | ||
| —— | $1.69M+33.3% | $1.27M+50.0% | $847K+100% | $423.5K— | ||
| —— | —— | —— | $5.14M+596% | -$1.04M+85.9% | ||
| -$6.2M-457% | $1.74M+2,346% | $71K— | —— | —— | ||
| -$7.77M-3.8% | -$7.48M-3.8% | -$7.2M-3.9% | -$6.93M-3.9% | -$6.67M-4.0% | ||
| -$18.34M+5.2% | -$19.35M-160% | -$7.45M-344% | $3.05M-67.7% | $9.46M-20.2% | ||
| $38.41M+0.3% | $38.29M+2.3% | $37.43M+5.1% | $35.63M+7.2% | $33.23M+7.0% | ||
| $5.68M-3.4% | $5.88M+3.5% | $5.69M+3.4% | $5.5M+3.4% | $5.31M+3.4% | ||
| -$512K+10.3% | -$571K+7.3% | -$616K+3.6% | -$639K+14.2% | -$745K+2.7% | ||
| $532K-68.6% | $1.7M-34.3% | $2.58M-18.3% | $3.16M-17.5% | $3.83M+23.5% | ||
| $103.13M— | $0-100% | $17.88M-50.0% | $35.76M-33.3% | $53.65M-25.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $3.15M-7.8% | $3.41M-9.2% | $3.76M-14.2% | $4.38M-17.5% | $5.31M-15.6% | ||
| -$66.91M+4.0% | -$69.73M— | —— | —— | —— | ||
| -$7.77M-3.8% | -$7.48M-3.8% | -$7.2M-3.9% | -$6.93M-3.9% | -$6.67M-4.0% | ||
| —— | —— | —— | —— | —— | ||
| $53K-29.3% | $75K-96.8% | $2.37M-0.1% | $2.37M-86.5% | $17.52M0.0% | ||
| -$151.59M+14.5% | -$177.24M+20.4% | -$222.6M+10.8% | -$249.43M-21.8% | -$204.71M-1.5% | ||
| -$151.59M+14.5% | -$177.24M+20.4% | -$222.6M+10.8% | -$249.43M-21.8% | -$204.71M-1.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Sutro Biopharma generate?
- Sutro Biopharma (STRO) generated -$151.6M in operating cash flow over the trailing twelve months.
- What is Sutro Biopharma's free cash flow?
- After $627.0K of capital expenditures, Sutro Biopharma's free cash flow was -$151.6M over the trailing twelve months, up 25.9% year over year.
- Where does Sutro Biopharma's cash flow data come from?
- Every line is extracted from Sutro Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
